Whole-body Hyperthermia for Moderate to Severe Depressive Disorder
Launched by UNIVERSITÄT DUISBURG-ESSEN · Apr 5, 2019
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unipolar depression (diagnosed according to the DSM-IV)
- • Moderate depression: 17-23 points on the HAMD-17 or severe depression: ≥24 points on the HAMD-17
- Exclusion Criteria:
- • Participants who did not respond to prior antidepressant drug treatment, electroconvulsive therapy, or sleep deprivation (therapy-resistant depression)
- • Acute suicidality
- • Prior treatment with whole-body hyperthermia
- • Contraindications to hyperthermia treatment: acute or feverish infections, severe cardiovascular diseases (e.g. angina pectoris, heart failure, thrombosis, bleeding diathesis), severe gastrointestinal diseases (e.g. renal insufficiency, hepatitis, liver cirrhosis, peptic ulcer), severe neurological diseases (e.g. epilepsy, multiple sclerosis, cerebrovascular malformations or brain tumors), severe endocrine diseases (e.g. hyperthyroidism), or oncological diseases without remission
- • Participants taking anti-inflammatory or immunosuppressive drugs
- • Participants with severe psychiatric comorbidities (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, dementia, ADHD, obsessive-compulsive disorder, PTSD, alcohol or drug addiction)
- • Women during pregnancy and breastfeeding
- • Lack of ability to consent
About Universität Duisburg Essen
The Universität Duisburg-Essen is a prominent academic institution in Germany, renowned for its commitment to research and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its interdisciplinary expertise and state-of-the-art facilities to advance clinical research initiatives. With a focus on improving patient outcomes, the university actively collaborates with healthcare professionals, industry partners, and regulatory bodies to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to enhancing clinical knowledge and fostering new therapeutic approaches, Universität Duisburg-Essen plays a pivotal role in the evolution of modern healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, , Germany
Essen, , Germany
Patients applied
Trial Officials
Gustav Dobos, Prof. MD
Study Director
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials